linjc16/ctgov huggingface dataset:
Diagnostic Outcomes of Patients Presenting With Per Rectal Bleed in Surgical Departments of Services Hospital Lahore

Study Overview
=================
Brief Summary
-----------------
It is a cross sectional study in which investigators will be recruiting patients of any sex above 12 years of age who will present to surgical outdoor with per rectal bleed. Investigators will then follow them through investigations to reach a certain diagnosis. Then investigators will be able to compile the data of diseases and their frequency, which are presenting with rectal bleed in their setup.

Official Title
-----------------
Diagnostic Outcomes of Patients Presenting With Per Rectal Bleed in Surgical Departments of Services Hospital Lahore

Conditions
-----------------
Rectal Bleeding

Intervention / Treatment
-----------------
* Diagnostic Test: procto sigmoidoscopy and biopsy if required


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient of any sex above 12 years old patients with rectal bleed in OPD Exclusion Criteria: Patient with acute rectal bleeding due to infection like dysentry Acute proctitis Acute colitis

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of diseases in patients with rectal bleed | outcome of this study is to discover the frequency of diseases which are presenting with rectal bleed in our setup like hemorrhoids, anal fissure or rectal carcinoma | 6 weeks |
Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

Study Overview
=================
Brief Summary
-----------------
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.

Official Title
-----------------
A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 Inhibitor

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Drug: GW869682


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Have a BMI within range 30.0 to 40.0kg/m2, inclusive. Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or post-menopausal per protocol definition). Exclusion criteria: History of eating disorders. Recent history of weight loss or gain. Had gastrointestinal surgery for treatment of obesity. Type 1 or type 2 diabetes mellitus. Have a positive urine drug screen. Have liver disease. Have hepatitis B, hepatitis C, or HIV antibodies. Have a thyroid disorder that is not under control with medication. Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or cancer). Are unable to participate in an exercise program. Have used weight loss drugs within 3 months before the start of the study. Are currently using warfarin, digoxin, oral anti-coagulants (other than aspirin and non-steroidal anti-inflammatory drugs), oral or injectable corticosteroids (inhaled & intranasal corticosteroids are permitted), or antiretroviral medications. Used of any investigational drug or device during the study or within 30 days prior to 1st dosing of study medication. High or low blood pressure.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GW869682|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage change in body weight from baseline to Week 12. |  | from baseline to Week 12. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood levels of GW869682 at the Week 2 and Week 11. |  | at the Week 2 and Week 11 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hunger, obesity, sodium-dependent glucose transporter, GW869682, body composition, SGLT2 inhibitor, weight loss
Pilot Efficacy Study of the Stendo Pulsating Suit in Patient With Leg Lymphoedema

Study Overview
=================
Brief Summary
-----------------
This study aims at evaluating the efficacy of the Stendo pulsating suit in patients with a leg lymphedema hospitalized for intensive Complex Decongestive Physiotherapy (CDP). This study is a pilot controlled randomized study with two arms.

Official Title
-----------------
Pilot Efficacy Study of the Stendo Pulsating Suit in Patient With Leg Lymphoedema

Conditions
-----------------
Primary Lower Limb Lymphedema, Secondary Lower Limb Lymphedema

Intervention / Treatment
-----------------
* Other: Current intensive CDP
* Other: intensive CDP where Stendo pulsating suit replaces pressotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a primary or secondary lympedema clinically diagnosed (Stemmer Sign) of one or two legs. Patient with a lympedema stage II (persistent) or III according to the classification of the International Society of Lymphoedema (ISL) Patient aged 18 or more Exclusion Criteria: Patient with a severe heart, kidney or liver failure, Patient with an advanced obstructive arterial disease Patient with a recent and progressive deep venous thrombosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard intensive CDP<br>This arm is the controlled group ; patients in that group will undergo a current practice performed in the lymphology unit. | Other: Current intensive CDP<br>* Standard Intensive CDP including manual lymph drainage, pressotherapy and bandaging<br>|
| Experimental: Stendo group<br>This arm contitutes the group where the Stendo pulsating suit sessions are investigated in the frame of the CDP in replacement of the pressotherapy sessions. | Other: intensive CDP where Stendo pulsating suit replaces pressotherapy<br>* The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| volume of the most affected leg | Change in % of the volume of the most affected leg according to disk model method | baseline ; after 5 days intensive CDP | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Life | 36 health survey questionnaire (SF-36) and Visual Analogical Scale | baseline ; after 5 days intensive CDP | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulsating suit, lymphedema, leg volume
Chinese Pregnant Woman Cohort Study

Study Overview
=================
Brief Summary
-----------------
Purpose To determine the relationship between maternal lifestyle and obstetric and neonatal outcomes. Methods and analysis This is a multicentre, prospective, cohort study including more than 5000 participants in 24 hospitals in 12 provinces from July 2017 to July 2018 in China. Maternal lifestyle (environmental exposures, diet, physical activity, sleeping, psychology and economics) and metabolic status will be collected by the electronic self-administered questionnaire at the first, second and third trimesters and 42 days postpartum, respectively. Obstetric and neonatal outcomes and metabolic status recorded by a clinical research coordinator. Descriptive statistics will be used to investigate the outcomes of maternal and newborn across China. Logistical regression and covariance analysis will be used to determine the relationship between maternal lifestyle and obstetric and neonatal outcomes. SAS statistical software will be used for data analysis. Ethics and dissemination Permission for the study was obtained from Chinese Academy of Medical Sciences and Peking Union Medical College. Ethics approval was obtained from the Ethics Review Committee at Department of Scientific Research, Peking Union Medical College Hospital, Beijing, China. The results will be published in peer-reviewed journals or disseminated through conference presentations.

Official Title
-----------------
Chinese Pregnant Woman Cohort Study

Conditions
-----------------
Pregnancy Related, Pregnancy Disease, Pregnancy, Infant, Risk Factor

Participation Criteria
=================
Eligibility Criteria
-----------------
The participants were pregnant women who satisfied the following criteria: (1) ≥16 years old; (2) at 5-12 weeks' gestational; (3) able to complete the questionnaire; (4) permanent residents in the study locations; and (5) willing to sign the consent form.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>This cohort study only set up a group. We will follow up and observe the pregnant women's lifestyle during pregnancy in order to find the risk factors of adverse pregnancy outcomes. We will divide the participants into more than one group according to the variables（e.g. age, smoking status, drinking status, sleep pattern .etc.） | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| preterm birth | The doctors will record the delivery time | 2017.10.1-2019.3.1 | 
| birth weight | The doctors will record the birth weight | 2017.10.1-2019.3.1 | 
| birth defects | The doctors will record the birth defects | 2017.10.1-2019.3.1 |
Amflow-device Can Help Proper Ambu-bag Ventilation

Study Overview
=================
Brief Summary
-----------------
This is a simulation study with a prospective randomized cross-over design. The aim of this study is to evaluate whether Amflow-assisted ambu-bag can delivery the accurate tidal volume compare to ordinary ambu-bag

Detailed Description
-----------------
Ambu-bag ventilation is an essential skill to the patients who needed ventilatory support. However, the delivery of appropriate amount of tidal volume by ordinary manual bag ventilation may be difficult. In addition, it require adequate training to rescurer. We hypothesised that an Amflow assist ambu bag may be helpful to delivery accurate tidal volumes to the patients. Participants performed bag-valve ventilation to manikin by ordinary technique and Amflow assist technique in our simulation centre. We measured each ventilation rate and ventilation volume in simulated scenario and we compare those between two technique.

Official Title
-----------------
Evaluation of an Amflow-device Assist Ambu-bagging to Improve Accuracy of Tidal Volumes Delivered.

Conditions
-----------------
Ventilation Therapy; Complications

Intervention / Treatment
-----------------
* Device: Amflow
* Device: Ambu bag


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A healthy senior medical students who agree attend this study. Exclusion Criteria: A participants who does not agree attend this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Amflow assist ambu bag ventiation<br>Newely developed method (Amflow assist ambu bag ventilation) | Device: Amflow<br>* Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag<br>|
| Experimental: Ambu bag ventilation<br>Ordinary method (ambu bag ventilation | Device: Ambu bag<br>* Participants ventilated the simulated patients by ambu bag<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tidal volume | We compared mean tidal volume delivered to manikins between two techniques | 6 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ventilation Rate | We compared mean ventilation rate between two techniques | 6 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ambu bag, ventilation, tidal volume
National Study AEC COVID-19

Study Overview
=================
Brief Summary
-----------------
Currently there is an important need to know the evolution, results and associated mortality of patients undergoing surgical intervention in Spain during the SARS-CoV-2 pandemic. With a national data collection, information could be obtained to guide the management of this group of complex patients operated on during the COVID-19 pandemic, with the aim of improving their treatment in the event of a second wave. The great spread of the virus and the difficulty in controlling it over time makes it a high priority for the scientific community in order to face new outbreaks. The national study AEC COVID-19 is a collaborative study (in the style of those carried out at European level such as Eurosurg, Globalsurg, etc.) that aims to know the evolution, results and associated mortality of patients undergoing surgical intervention in Spain during the SARS-CoV-2 pandemic. It is an observational study, with anonymized and coded data, which aims to demonstrate the following hypotheses: Patients with COVID-19 have high mortality. Patients with both oncological and benign pathologies have high morbidity. The situation / follow-up at 7 days and 30 days after the intervention will be included in each patient.

Official Title
-----------------
National Study AEC COVID-19 on Patients Undergoing Surgical Intervention During the SARS-CoV-2 Pandemic.

Conditions
-----------------
Mortality

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients who undergo a surgical procedure during the pandemic Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Patient who died after surgery 30 days after the surgical procedure | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morbidity | Complictaions after surgery | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID, Surgery
Motivations and Barriers to Participating in Ophthalmology Research Projects

Study Overview
=================
Brief Summary
-----------------
The primary objective of this project is to understand the reasons why patients agree / disagree to take part in ophthalmology research. This will be done by asking participants to complete a Research Questionnaire.

Official Title
-----------------
Motivations and Barriers to Participating in Ophthalmology Research Projects

Conditions
-----------------
Eye Diseases

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 16 years old Willing to participate by completing the questionnaire Must be able to speak and read English Exclusion Criteria: Under 16 years of age Not willing to complete the questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|Patients will be asked to complete a questionnaire about the reasons why they agree / decline to take part in research.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of motivations to participating in ophthalmology research. | Questionnaire | 5 years | 
| Assessment of barriers in participating in ophthalmology research | Questionnaire | 5 years |
Cognitive Behaviour Therapy for Patients With IBS

Study Overview
=================
Brief Summary
-----------------
Irritable bowel syndrome (IBS) affects approximately 10-15% of the adult population. This condition is characterized by abdominal pain, altered bowel habit, abdominal bloating and reduced quality of life. Options for treating IBS include pharmacotherapy, psychotherapy, hypnotherapy and cognitive behavior therapy (CBT). Available data on the effectiveness of CBT in IBS patients in Israel are scarce. The aim of the present study is to assess effectiveness of CBT as compared with standard therapy for IBS patients in Israel The course of CBT consisted of up to six 40 min sessions, and included education about IBS and techniques to reduce focusing on symptoms and to manage stress.Standard therapy includs life style modifications. The primary outcome measure was the score on a symptom-severity scale specific to IBS.

Detailed Description
-----------------
Symptomatic treatment of patients would not be modified

Official Title
-----------------
Cognitive Behavior Therapy (CBT) as Compared With Standard Therapy for Patients With IBS and Other Functional Gastrointestinal Disorders

Conditions
-----------------
Irritable Bowel Syndrome, Constipation, Abdominal Pain, Depression

Intervention / Treatment
-----------------
* Behavioral: Diet modifications
* Behavioral: Cognitive behavioral therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-75 IBS Exclusion Criteria: Malignancy Known psychiatric disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Diet modifications<br>Diet consultation and life style modifications for 6 sessions | Behavioral: Diet modifications<br>* Diet consultation<br>* Other names: Diet;|
| Active Comparator: Cognitive therapy<br>6 sessions of cognitive behavioral therapy | Behavioral: Cognitive behavioral therapy<br>* Cognitive behavioral therapy<br>* Other names: CBT;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom score |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life assessment |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructed constipation, Quality of life
Medtronic Cardiac Surgery PMCF Registry

Study Overview
=================
Brief Summary
-----------------
This registry is being conducted to support ongoing post-market surveillance activities.

Official Title
-----------------
Medtronic Cardiac Surgery Post Market Clinical Follow-up Registry

Conditions
-----------------
Valve Disease, Heart

Intervention / Treatment
-----------------
* Device: Surgical Heart Valve Repair Products
* Device: Surgical Heart Valve Replacement Products


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements Patient has or is intended to receive or be treated with an eligible product Patient is within enrollment window of treatment/therapy received at the time of their initial Registry enrollment, or meets criteria for retrospective enrollment Exclusion Criteria: Patient who is, or is expected to be, inaccessible for follow-up Patient prohibited from participation by local law Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or device study that may confound results
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Surgical Valve Replacement and/or Repair Patients<br> | Device: Surgical Heart Valve Repair Products<br>* Surgical heart valve repair products.<br>Device: Surgical Heart Valve Replacement Products<br>* Surgical heart valve replacement products.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify unique failure modes |  | 10 years | 
| Identify trends in adverse device effects |  | 10 years |